Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received the Integrated Reporting Encouragement Prize in the 6th WICI Japan Award for Excellence in Integrated Reporting. This is the first time that Sysmex has won this award.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) will provide high-density lipoprotein (HDL) function measurement (for research) as a research assay service, leveraging the Company’s measurement platform and assay-related expertise. Through this service, Sysmex aims to contribute toward the creation of new methods for diagnosing and treating atherosclerosis-related diseases.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), a Japanese in vitro diagnostics company, and MolecularMD Corporation (HQ: Portland, Oregon, United States; President and CEO: Dan Snyder), a molecular diagnostics company, announced today a master collaboration agreement targeting the challenges in current and future companion diagnostics (CDx)* development and commercialization needed to accelerate precision medicine.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has launched a super-resolution fluorescence microscope, the HM-1000 single-molecule fluorescence microscope, for research use. Employing super-resolution imaging technology, the HM-1000 achieves high spatial resolution1 (of less than 40nm), going beyond the limits of conventional fluorescence microscopes. As a result, the HM-1000 can be used for minute observation, such as the morphology of tiny proteins that exist within cells and the distribution of genes. Sysmex expects the HM-1000 to contribute toward effective R&D related to next-generation therapeutic drugs and diagnostic methods that will lead toward the realization of personalized medicine, as well as to developments in cellular biology.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to reinforce its global R&D structure to accelerate R&D that leverages local characteristics. We aim to foster early-stage innovation through the acquisition of opportunities to participate in projects headed by national and regional government entities, proactive recruitment of local R&D personnel, and enhanced collaboration with overseas subsidiaries. To begin, we incorporated our R&D Center in Europe. We believe this move will enhance its agility, accelerating such multifaceted R&D activities as technology searches and development in Europe, as well as supporting market launches.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the third consecutive year.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), Toppan Printing Co., Ltd. (HQ: Tokyo, Japan; President & Representative Director: Shingo Kaneko) and RIKEN GENESIS Co., Ltd. (HQ: Tokyo, Japan; President & CEO; Naoto Kondo) have jointly developed the LW-100 Gene Measurement Analyzer (research use only) and a group of related reagents as a system to fully automate testing to detect gene mutations in cancer tissue.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) provides notice that the CyFlow™ Counter System (CyFlow™ Counter with CD4 easy count kit and CD4% easy count kit), developed and produced by its subsidiary Sysmex Partec (“Partec”), has received WHO prequalification. This testing system helps diagnose and monitor the immune status of people infected with HIV by checking CD4 in human blood samples. This marks the first time a Sysmex Group product has received WHO prequalification.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has established a new subsidiary in Egypt and will begin conducting direct sales and services with the aim of expanding its business in the Middle East.
Sysmex Corporation (HQ: Kobe, Japan: Chairman and CEO: Hisashi Ietsugu), the Foundation for Biomedical Research and Innovation at Kobe1 (Location: Kobe, Japan; President: Tasuku Honjo) and Kyoto University (Location: Kyoto, Japan; President: Juichi Yamagiwa) have begun joint research related to the Drug Discovery Innovation Program: Developing Technologies for Diagnosing Immunological Diseases, which the Foundation is promoting. Through joint research, the three organizations aim to create a diagnostic system that will enable the early detection of autoimmune disease and chronic inflammatory disease.